Dasatinib dosage for the treatment of gastrointestinal stromal tumors

The application of dasatinib in the treatment of gastrointestinal stromal tumors (GIST), especially in patients who are resistant or intolerant to imatinib, has shown certain efficacy.

For patients with gastrointestinal stromal tumors, if dasatinib treatment is considered, the usual dosage may be based on similar clinical trials or the physician's experience. According to publicly released information, patients take dasatinib by mouth daily, and the dose may be adjusted based on their condition and tolerability. In some studies, patients may start at a lower dose, such as 50 mg twice daily, and then gradually increase to 70 mg twice daily based on tolerance.

In a single-arm, multicenter, Phase 2 trial in patients with imatinib-resistant advanced gastrointestinal stromal tumors, participants received an initial dose of oral dasatinib at 50 mg twice daily for 2 weeks. If tolerated by the patient, the dose may be increased to 70 mg twice daily to control tumor progression or unacceptable toxicity. This dosing regimen demonstrates the potential efficacy of dasatinib in specific patient populations.

The dosage of dasatinib should be adjusted individually based on the patient's specific conditions. Doctors will determine the appropriate dosage based on factors such as the patient's weight, severity of the condition, tolerance and the presence of other complications. During treatment, your doctor may make dosage adjustments based on the patient's response and tolerance. Doctors may reduce the dose or suspend treatment if the patient experiences serious adverse reactions or is unable to tolerate the current dose. Patients should be monitored and followed regularly during dasatinib treatment to evaluate treatment effects and adverse reactions. The doctor will promptly adjust the treatment plan based on the monitoring results.